文献速递类风湿关节炎

生物制剂与炎症对类风湿关节炎患者血脂水平及心血管风险的影响

Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients.
PubMed 文献 · Semin Arthritis Rheum · 2024-06-29

研究纳入1698例启动bDMARD的类风湿关节炎患者,随访6个月,发现托珠单抗组血脂显著升高但Reynolds风险评分在各生物制剂间相似,Framingham风险评分在托珠单抗组升高;CRP变化与血脂变化显著相关,LDL-C升高独立于临床应答。

要点

  • 托珠单抗组血脂显著升高,但Reynolds风险评分在各生物制剂间相似。
  • Framingham风险评分在托珠单抗治疗组升高。
  • CRP变化与血脂变化显著相关,LDL-C升高独立于临床应答。

核心结论

  • bDMARD治疗期间血脂中度升高与Reynolds风险评分所评估的心血管风险增加无关,与所启动的bDMARD种类无关。
  • 中介分析显示CRP变化与血脂变化显著相关。

研究设计与样本

  • 研究纳入启动bDMARD的类风湿关节炎患者,在基线、3个月和6个月时进行评估,共分析1698次bDMARD启动。
  • 采用纵向混合效应模型分析单个生物制剂与血脂水平、Reynolds风险评分和Framingham风险评分变化的关联。
  • 采用结构方程模型分析CRP、临床疾病活动指数(CDAI)或肿胀关节数对血脂变化的中介作用。
  • 估计CRP变化与LDL变化之间的相关性,并比较基线LDL-C较低(<90 mg/dl)与较高(90-130和>130 mg/dl)患者6个月时LDL-C的变化。
  • 评估各基线LDL-C组间LDL-C变化与疾病活动度改善之间的关联。

主要发现

  • 启动托珠单抗的患者血脂水平显著升高,但3个月和6个月时Reynolds风险评分在所有生物制剂间相似。
  • 接受托珠单抗治疗的患者Framingham风险评分升高。
  • 中介分析显示CRP对血脂水平的影响具有统计学显著性。
  • LDL-C自基线的升高独立于临床应答。
  • 在所有研究的bDMARD中均观察到基线CRP变化与LDL-C变化之间的关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular disease (CVD) is the main cause of mortality in Rheumatoid Arthritis (RA). OBJECTIVE: To investigate the effect of biologic disease modifying anti-rheumatic drugs (bDMARDs) on lipids and CVD risk and evaluate associations with changes in systemic inflammation. METHODS: Patients with RA initiating a bDMARD were evaluated at baseline, 3 and 6 months later. Longitudinal mixed effects models examined the association of individual biologics with changes in lipid levelsm Reynolds Risk Score (RRS) and Framingham risk score. Mediation by CRP, clinical disease activity index (CDAI) or swollen joint count on lipid changes were modeled using structural equation models. The correlation between CRP changes and LDL changes was estimated. Changes of LDL-C at 6 months among patients with low baseline LDL-C (<90 mg/dl) vs higher baseline LDL-C(90-130, and >130 mg/dl) were compared. The association between LDL-C changes across baseline LDL-C groups and disease activity improvement was evaluated. RESULTS: 1698 bDMARD initiations were analyzed. Patients initiating tocilizumab had a significant increase in lipid levels but RRS at 3 and 6 months was similar across all biologics. Framingham risk score increased for patients treated with tocilizumab. Mediator analyses were statistically significant for the effects of CRP on lipid levels. Increases in LDL-C from baseline were independent of clinical response. An association of changes from baseline CRP and LDL-C were observed across all of the bDMARDs studied. CONCLUSION: Moderate increases in lipid levels on bDMARD treatment were not associated with an increased CVD risk by RRS regardless of the bDMARD initiated. Changes in CRP were significantly associated with changes in lipids in a mediator analysis.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Pappas DA, Reed G, Kane K, et al. Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients. Semin Arthritis Rheum. 2024. PMID: 38991379. doi:10.1016/j.semarthrit.2024.152504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。